Virginia Kaklamani, MD, DSc, presents a case of metastatic breast cancer, initially responsive to first-line aromatase and CDK4/6 inhibitors, that progressed after 32 months. She explores using biomarker testing to identify ESR1 and other actionable mutations potentially causing endocrine resistance, guiding the transition to second-line therapy.
Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.
Stephen Williams, MD, MBA, MS, FACS, FACHE, discusses new and exciting developments in the bladder cancer treatment landscape.
Raajit K. Rampal, MD, PhD, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.
Thomas J. Herzog, MD, discusses the efficacy data seen in a subgroup analysis of the phase 2 AMPECT study evaluating nab-Sirolimus for patients with perivascular epithelioid sarcoma.
Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Thomas J. Herzog, MD, discusses the safety findings of nab-Sirolimus in a subgroup analysis of the phase 2 AMPECT study looking at patients with perivascular epithelioid sarcoma.
Thomas J. Herzog, MD, discusses the importance of patients seeing a gynecologist oncologist or a sarcoma doctor for gynecologic perivascular epithelioid sarcomas.
Elizabeth Plimack, MD discusses recent results from the phase 2 nivolumab and cabozantinib trial in nccRCC.
Dr. Motzer discusses the major challenges and mitigation strategies for managing high-grade adverse events with nccRCC regimens.
Dr. Motzer compares combination IO + TKIs to single agent ICI or TKI therapy regarding efficacy in nccRCC patients.
Abdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Binod Dhakal, MD, explores how CAR-T therapy may impact the future treatment landscape for R/R MM, including current unmet needs and clinical pearls for community oncologists treating patients with R/R MM.
Binod Dhakal, MD, shares clinical perspectives on using CAR-T therapy in R/R MM, highlighting the implications of the latest data for community oncologists and their patients.
Binod Dhakal, MD, discusses the current approach to sequencing CAR-T therapy for patients with R/R MM, including the impact of emerging bispecific antibodies and the potential role of CAR-T in earlier lines of therapy.
Binod Dhakal, MD, explores clinicians' safety concerns with using CAR-T therapy in R/R MM, including notable adverse events from recent clinical data and strategies for managing these events in practice.
Binod Dhakal, MD, discusses the latest results from the KarMMA-3 study, which investigated idecabtagene vicleucel (ide-cel) for patients with R/R MM, covering study design, patient population, and key takeaways.
Binod Dhakal, MD, reviews the latest results from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel (cilta-cel) versus standard of care in patients with R/R MM, including study design, patient population, and key efficacy findings.
Binod Dhakal, MD, explores the role of CAR-T cell therapy in R/R MM, including an overview of the process, patient selection criteria, and identifying suitable candidates.
Binod Dhakal, MD, discusses the current standard of care for R/R MM, highlighting how treatment decision-making changes for patients who are refractory to lenalidomide and/or bortezomib.
Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.
Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.
Brian Slomovitz, MD, MS, FACOG, discusses the potential use of tisotumab vedotin-tftv in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.
Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.
Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.
Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.
A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.
Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.